Lack of efficacy of standard doses of ivermectin in severe COVID-19 patients

Ivermectin has recently shown efficacy against SARS-CoV-2 in-vitro. We retrospectively reviewed severe COVID-19 patients receiving standard doses of ivermectin and we compared clinical and microbiological outcomes with a similar group of patients not receiving ivermectin. No differences were found b...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	PloS one 2020-11, Vol.15 (11), p.e0242184, Article 0242184
Hauptverfasser:	Camprubi, Daniel, Almuedo-Riera, Alex, Marti-Soler, Helena, Soriano, Alex, Hurtado, Juan Carlos, Subira, Carme, Grau-Pujol, Berta, Krolewiecki, Alejandro, Munoz, Jose
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Antibodies, Monoclonal, Humanized - therapeutic use Antiviral drugs Betacoronavirus - isolation & purification Biology and life sciences Clinical trials Coronavirus Infections - diagnosis Coronavirus Infections - drug therapy Coronavirus Infections - virology Coronaviruses COVID-19 COVID-19 Drug Treatment Disease transmission Dosage and administration Drug dosages Drug therapy Female Hospitals Humans Immunosuppressive Agents - therapeutic use Infections Ivermectin Ivermectin - therapeutic use Male Medical research Medicine and Health Sciences Middle Aged Multidisciplinary Sciences Nasopharynx - virology Pandemics Patient outcomes Patients Physical Sciences Pneumonia, Viral - diagnosis Pneumonia, Viral - drug therapy Pneumonia, Viral - virology Research and Analysis Methods Retrospective Studies SARS-CoV-2 Science & Technology Science & Technology - Other Topics Severe acute respiratory syndrome Severe acute respiratory syndrome coronavirus 2 Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Ivermectin has recently shown efficacy against SARS-CoV-2 in-vitro. We retrospectively reviewed severe COVID-19 patients receiving standard doses of ivermectin and we compared clinical and microbiological outcomes with a similar group of patients not receiving ivermectin. No differences were found between groups. We recommend the evaluation of high-doses of ivermectin in randomized trials against SARS-CoV-2.
ISSN:	1932-6203 1932-6203
DOI:	10.1371/journal.pone.0242184